Anemia is a common condition in preterm infants and is closely linked to the development of ROP. Iron deficiency exacerbates hypoxia and oxidative stress, contributing to abnormal retinal vessel ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved WELIREG ® (belzutifan), ...

Median time to onset of anemia was 29 days (range: 1 day to 22.1 months). Of the patients with anemia, 20% received transfusions only, 26% received ESAs only, and 6% received both transfusion and ESAs ...

RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma. The objective response rate (ORR) for belzutifan in patients with ...

Anemia is a common condition in premature infants, particularly those at risk for retinopathy of prematurity (ROP). While the relationship between anemia and ROP risk remains complex, recent studies ...

Casdatifan, an HIF-2α inhibitor, showed a 33% objective response rate in ccRCC patients at a 100 mg daily dose. The drug targets hypoxia-inducible factor-2 alpha to disrupt tumor-promoting mechanisms ...

Acceptance based on objective response rate data from the Phase 2 LITESPARK-015 trial evaluating WELIREG in certain patients with advanced PPGL If approved, WELIREG would be the only available therapy ...

Chronic kidney disease (CKD) patients often suffer from complications such as anemia as the kidney function declines. More than 25% of CKD hemodialysis patients in China are complicated with renal ...